We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Actavis Fails to Win FDA Change in Vyvanse Exclusivity Decision
Actavis Fails to Win FDA Change in Vyvanse Exclusivity Decision
November 10, 2009
The FDA has affirmed five-year market exclusivity for Shire’s Vyvanse — a decision generic maker Actavis is challenging in a lawsuit against the agency.